Back to Search
Start Over
A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
- Source :
-
Journal of neuro-oncology [J Neurooncol] 2014 Nov; Vol. 120 (2), pp. 423-30. Date of Electronic Publication: 2014 Aug 07. - Publication Year :
- 2014
-
Abstract
- We proposed to identify the efficacy of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery (SRS)/surgery in brain metastases from patients with non-small cell lung cancer (NSCLC) and clarify the association between treatment outcome and EGFR gene mutation status. A total of 282 patients with NSCLC brain metastases who underwent WBRT/SRS/surgery alone or in combination with TKI were enrolled in our study from 2003-2013. Amplification mutation refractory system technology was used to determine the EGFR mutation status in 109 tissue samples. EGFR mutation detection was performed in 109 patients with tumor tissues. The EGFR positive rate was 50 % (55/109), including 26 exon 19 deletions and 24 L858R mutations. The median follow-up time was 28 months. The median overall survival, median progression-free survival of intracranial disease, and median progression-free survival of extracranial disease was significantly longer for patients with TKI treatment (31.9 vs 17.0 months, P < 0.0001; 19.8 vs 12.0 months, P < 0.0001; and 19.6 vs 12.3 months, P < 0.0001; respectively). In subgroup analysis within the TKI group, patients harboring EGFR mutations had better extracranial disease control (20.4 vs 14.1 months, P = 0.032). Administration of TKI agents with conventional therapy compared with conventional therapy alone might be beneficial for overall survival, progression-free survival of intracranial disease and progression-free survival of extracranial disease in patients with brain metastases from NSCLC independent of EGFR mutations.
- Subjects :
- Adenocarcinoma mortality
Adenocarcinoma pathology
Adenocarcinoma therapy
Adult
Aged
Brain Neoplasms mortality
Brain Neoplasms secondary
Brain Neoplasms therapy
Carcinoma, Non-Small-Cell Lung mortality
Carcinoma, Non-Small-Cell Lung pathology
Carcinoma, Non-Small-Cell Lung therapy
Combined Modality Therapy
Cranial Irradiation
Female
Follow-Up Studies
Humans
Lung Neoplasms mortality
Lung Neoplasms pathology
Lung Neoplasms therapy
Male
Middle Aged
Neoplasm Staging
Prognosis
Protein Kinase Inhibitors therapeutic use
Radiosurgery
Retrospective Studies
Survival Rate
Adenocarcinoma genetics
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Brain Neoplasms genetics
Carcinoma, Non-Small-Cell Lung genetics
ErbB Receptors genetics
Lung Neoplasms genetics
Mutation genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1573-7373
- Volume :
- 120
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of neuro-oncology
- Publication Type :
- Academic Journal
- Accession number :
- 25098700
- Full Text :
- https://doi.org/10.1007/s11060-014-1570-7